MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said ...

MannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes Association’s 85th Scientific Sessions in Chicago, which was held from June 20 to June 23, 2025.

Ultra-rapid insulins are used to manage type 1 and type 2 diabetes. Learn about the different types, their effectiveness, and how they can provide mealtime flexibility.

The global health landscape is evolving with Brazil battling bird flu-related trade restrictions, Nestle USA eliminating synthetic food colors by 2026, and Novo Nordisk launching a weight-loss drug in ...

Recent advancements in inhaled insulin for type 1 diabetes and once-weekly insulin for type 2 diabetes present promising alternatives to injections. Additionally, genetically engineered skin grafts ...

(Reuters) -Children with diabetes who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the skin, researchers reported at the American Diabetes Association ...

(Reuters) -Children with diabetes who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the skin, researchers reported at the American Diabetes Association ...